Physician profile
Carla Pham
NPI 1740711084
$23,192.54
in general payments reported to CMS, 2019-2025
27 companies · $7,463 in 2025
The $7,463 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,569 · 2022: $1,261 · 2023: $2,476 · 2024: $10K · 2025: $7,463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,643 · Consulting Fee: $7,945 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,058 · Travel and Lodging: $1,707 · Education: $9.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,643.04 |
| Consulting Fee | $7,945.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,058.00 |
| Travel and Lodging | $1,706.93 |
| Education | $9.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $13,651.99 | 2021-2025 | |
| Biogen, INC. | $1,945.70 | 2021-2025 | Vumerity, Tysabri, Plegridy |
| Emd Serono, INC. | $1,879.04 | 2021-2025 | Mavenclad |
| Genentech USA, INC. | $1,656.27 | 2021-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Novartis Pharmaceuticals Corporation | $1,342.06 | 2021-2025 | |
| Celgene Corporation | $575.76 | 2021-2025 | Zeposia |
| Mallinckrodt Hospital Products INC. | $349.61 | 2021-2024 | Acthar |
| Alexion Pharmaceuticals, INC. | $304.14 | 2022-2023 | Ultomiris, Soliris |
| Tg Therapeutics, INC. | $223.72 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $175.55 | 2021 | |
| Axsome Therapeutics, INC. | $155.94 | 2023-2025 | Sunosi |
| Teva Pharmaceuticals USA, INC. | $117.22 | 2021 | |
| Genentech, INC. | $116.37 | 2024-2025 | Ocrevus |
| E.R. Squibb & Sons, L.L.C. | $99.50 | 2022 | |
| Cycle Pharmaceuticals INC | $89.07 | 2025 | Tascenso Odt, Bafiertam |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $79.32 | 2022-2024 | Ampyra, Inbrija |
| Banner Life Sciences, LLC | $76.44 | 2021-2023 | |
| Mylan Specialty L.P. | $59.05 | 2022-2024 | Glatiramer Acetate |
| Vanda Pharmaceuticals INC. | $56.51 | 2025 | Ponvory |
| Avanir Pharmaceuticals, INC. | $55.42 | 2021-2022 | |
| Sandoz INC. | $34.18 | 2024 | |
| Merz Pharmaceuticals, LLC | $34.11 | 2024 | Ampyra |
| Abbvie INC. | $32.38 | 2022-2024 | |
| Ani Pharmaceuticals, INC. | $31.05 | 2024 | Purified Cortrophin Gel |
| Sanofi-Aventis U.S. LLC | $18.67 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $17.85 | 2023 | Nuedexta |
| Sumitomo Pharma America, INC. | $15.62 | 2025 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carla Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.